BENGALURU (Reuters) – India’s Syngene International Ltd is aiming to deliver half a million vials of COVID-19 drug remdesivir through its distribution partners to the Indian market next month, its Chief Executive Officer told Reuters on Wednesday.
The company, which offers research and manufacturing services on a contractual basis to drugmakers across the world, has been supplying the drug in India under a licensing agreement with U.S.-based Gilead Sciences Inc.
It did not provide details on how many vials it has already delivered.
(Reporting by Anuron Kumar Mitra in Bengaluru)
